Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant PROSTVAC-V/F in High Risk Relapse After Radical Prostatectomy
NCT02772562Phase 2Terminated
- Sponsor
- Medical University of South Carolina
- Start
- Jul 2016
- Primary completion
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PROSTVAC-TRICOM in prostate cancer (PCa), sponsored by Medical University of South Carolina. Primary endpoint: Relapse-Free Survival at 2 years. Started Jul 2016; status: terminated.
02
Drugs
PROSTVAC-TRICOM
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02772562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772562.